Edgar Romero Ramírez

Mr. Edgar Romero Ramírez

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
CCCuevas-Lopez Cuevas-Lopez
Cuevas-Lopez Cuevas-Lopez
EREdgar Romero Ramírez
Edgar Romero Ramírez
FAFernando Garcia Arroyo
Fernando Garcia Arroyo
ETEdilia Tapia
Edilia Tapia
JUAN CARLOS LEON CONTRERASJUAN CARLOS LEON CONTRERAS
JUAN CARLOS LEON CONTRERAS
OAOmar Emiliano Aparicio-Trejo
Omar Emiliano Aparicio-Trejo
The incidence of kidney disease is increasing worldwide. Acute kidney injury (AKI) can strongly favor cardio-renal syndrome (CRS) type 3 development. However, the mechanism involved in CRS development is not entirely understood. In this sense, mitochondrial impairment in both organs has become a central axis in CRS physiopathology. This study aimed to elucidate the molecular mechanisms associated with cardiac mitochondrial impairment and its role in CRS development in the folic acid-induced AKI (FA-AKI) model. Our results showed that 48 h after FA-AKI, the administration of N-acetyl-cysteine (NAC), a mitochondrial glutathione regulator, prevented the early increase in inflammatory and cell death markers and oxidative stress in the heart. This was associated with the ability of NAC to protect heart mitochondrial bioenergetics, principally oxidative phosphorylation (OXPHOS) and membrane potential, through complex I activity and the preservation of glutathione balance, thus preventing mitochondrial dynamics shifting to fission and the decreases in mitochondrial biogenesis and mass. Our data show, for the first time, that mitochondrial bioenergetics impairment plays a critical role in the mechanism that leads to heart damage. Furthermore, NAC heart mitochondrial preservation during an AKI event can be a valuable strategy to prevent CRS type 3 development.